Vismodegib and sonidegib represent two FDA‐approved SMOi for the treatment of advanced and metastatic BCC, a nonmelanoma skin cancer driven by aberrant activation of HH/GLI signaling.1, 9 Despite striking therapeutic efficacy, severe side effects of SMOi drugs and frequent development of SMOi resistance pose major challenges to future HH pathway inhibitor therapies.3, 10, 11 Therefore, the identification of targets and drugs to be used in combination or as an alternative to SMOi, particularly in settings of SMOi‐resistance, is critical to improve anti‐HH‐therapies in oncology. Here, GLI1 is linked to skin basal cell carcinoma.